![]() | |
Clinical data | |
---|---|
ATC code |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
DrugBank | |
ChemSpider | |
UNII | |
ChEMBL | |
Chemical and physical data | |
Formula | C28H22Cl3N3O5 |
Molar mass | 586.85 g·mol−1 |
3D model ( JSmol) | |
| |
|
Cilofexor (also known as GS-9674) is a nonsteroidal farnesoid X receptor (FXR) agonist in clinical trials for the treatment of non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), [1] [2] [3] and primary sclerosing cholangitis (PSC). [4] [5] It is being investigated for use alone or in combination with firsocostat, selonsertib, [1] or semaglutide. [2] [6] In rat models [3] and human clinical trials [7] of NASH it has been shown to reduce fibrosis and steatosis, and in human clinical trials of PSC it improved cholestasis and reduced markers of liver injury. [4]
It is being developed by the pharmaceutical company Gilead Sciences. [8] [6]
![]() | |
Clinical data | |
---|---|
ATC code |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
DrugBank | |
ChemSpider | |
UNII | |
ChEMBL | |
Chemical and physical data | |
Formula | C28H22Cl3N3O5 |
Molar mass | 586.85 g·mol−1 |
3D model ( JSmol) | |
| |
|
Cilofexor (also known as GS-9674) is a nonsteroidal farnesoid X receptor (FXR) agonist in clinical trials for the treatment of non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), [1] [2] [3] and primary sclerosing cholangitis (PSC). [4] [5] It is being investigated for use alone or in combination with firsocostat, selonsertib, [1] or semaglutide. [2] [6] In rat models [3] and human clinical trials [7] of NASH it has been shown to reduce fibrosis and steatosis, and in human clinical trials of PSC it improved cholestasis and reduced markers of liver injury. [4]
It is being developed by the pharmaceutical company Gilead Sciences. [8] [6]